SLNO News

Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm

SLNO INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence?

SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline For Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

SLNO Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages SLNO Investors with Losses to Contact the Firm